A foreign exchange gain was recognized as non-operating income
CanBas Co.,Ltd. (the Company)
Foreign-currency-denominated accounts payable related to clinical trial preparation costs and other expenses, foreign-currency-denominated deposits, and other items
Fluctuations in foreign exchange conversion rates for foreign-currency-denominated accounts payable related to clinical trial preparation costs and other expenses, foreign-currency-denominated deposits, and other items
¥7.570 million (non-operating income and foreign exchange gain). For the cumulative fourth-quarter period, a total foreign exchange gain of ¥46.449 million was recognized as non-operating income.
Fourth-quarter accounting period of the fiscal year ending June 2026. A total foreign exchange gain of ¥46.449 million was also recognized for the cumulative fourth-quarter period.
This matter has been reflected in the Earnings Summary for the Fiscal Year Ended June 2026 [Japanese GAAP] (Non-consolidated), released today. Revisions to the earnings forecast: not disclosed
This matter has been reflected in the Earnings Summary for the Fiscal Year Ended June 2026 [Japanese GAAP] (Non-consolidated), released today. Other future actions and timing: not disclosed
| Item | Details |
|---|---|
| Event name | A foreign exchange gain was recognized as non-operating income |
| Date of occurrence | Fourth-quarter accounting period of the fiscal year ending June 2026 (1 April 2026 to 30 June 2026) |
| Subject Entity | CanBas Co.,Ltd. (the Company) |
| Target Locations / Products | Foreign-currency-denominated accounts payable related to clinical trial preparation costs and other expenses, foreign-currency-denominated deposits, and other items |
| Cause | Fluctuations in foreign exchange conversion rates for foreign-currency-denominated accounts payable related to clinical trial preparation costs and other expenses, foreign-currency-denominated deposits, and other items |
| Amount of Impact on Business Performance | ¥7.570 million (non-operating income and foreign exchange gain). For the cumulative fourth-quarter period, a total foreign exchange gain of ¥46.449 million was recognized as non-operating income. |
| Accounting period in which recognized | Fourth-quarter accounting period of the fiscal year ending June 2026. A total foreign exchange gain of ¥46.449 million was also recognized for the cumulative fourth-quarter period. |
| Impact on Earnings Forecast | This matter has been reflected in the Earnings Summary for the Fiscal Year Ended June 2026 [Japanese GAAP] (Non-consolidated), released today. Revisions to the earnings forecast: not disclosed |
| Outlook | This matter has been reflected in the Earnings Summary for the Fiscal Year Ended June 2026 [Japanese GAAP] (Non-consolidated), released today. Other future actions and timing: not disclosed |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This resulted from fluctuations in foreign exchange conversion rates for foreign-currency-denominated accounts payable related to clinical trial preparation costs and other expenses, foreign-currency-denominated deposits, and other items.